Literature DB >> 17465638

Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients.

Pei-Jun Zhou1, Da Xu, Zi-Cheng Yu, Xiang-Hui Wang, Kun Shao, Ju-Ping Zhao.   

Abstract

OBJECTIVES: To investigate the pharmacokinetics of mycophenolic acid (MPA) in Chinese adult renal allograft recipients, and to generate the validated model equations for estimation of the MPA area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) with a limited sampling strategy. PATIENTS AND METHODS: The pharmacokinetics in 75 Chinese renal allograft recipients treated with mycophenolate mofetil 2 g/day in combination with cyclosporin and corticosteroids were determined. The MPA concentration was assayed by high-performance liquid chromatography at pre-dose (C(0)) and at 0.5 (C(0.5)), 1 (C(1)), 1.5 (C(1.5)), 2 (C(2)), 4 (C(4)), 6 (C(6)), 8 (C(8)), 10 (C(10)) and 12 (C(12)) hours after dosing on day 14 post-transplant. Patients were randomly divided into: (i) a model group (n = 50) to generate the model equations by multiple stepwise regression analysis for estimation of the MPA AUC by a limited sampling strategy; and (ii) a validation group (n = 25) to evaluate the predictive performance of the model equations.
RESULTS: The mean MPA AUC(12) was 52.97 +/- 15.09 mg . h/L, ranging from 24.0 to 102.3 mg . h/L. The patient's age and serum albumin level had a significant impact on the MPA AUC(12). The correlation between the pre-dose MPA trough level (C(0)) and the MPA AUC(12) was poor (r(2) = 0.02, p = 0.33). Model equations 7 (MPA AUC(12) = 14.81 + 0.80 . C(0.5) + 1.56 . C(2) + 4.80 . C(4), r(2) = 0.70) and 11 (MPA AUC(12) = 11.29 + 0.51 . C(0.5) + 2.13 . C(2) + 8.15 . C(8), r(2) = 0.88) were selected for MPA AUC calculation in Chinese patients, resulting in good agreements between the estimated MPA AUC and the full MPA AUC(12), with a mean prediction error of +/-10.1 and +/-6.9 mg . h/L, respectively.
CONCLUSION: In Chinese renal allograft recipients, MPA pharmacokinetics manifest substantial interindividual variability, and the MPA AUC(12) tends to be higher than that in Caucasian patients receiving the same dose of mycophenolate mofetil. Two validated model equations with three sampling timepoints are recommended for MPA AUC estimation in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465638     DOI: 10.2165/00003088-200746050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  56 in total

Review 1.  Immunosuppressant drugs--the role of therapeutic drug monitoring.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  2001       Impact factor: 4.335

2.  Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.

Authors:  Aurélie Prémaud; Yannick Le Meur; Jean Debord; Jean-Christophe Szelag; Annick Rousseau; Guillaume Hoizey; Olivier Toupance; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2005-06       Impact factor: 3.681

Review 3.  Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

Authors:  Teun van Gelder; Yann Le Meur; Leslie M Shaw; Michael Oellerich; David DeNofrio; Curtis Holt; David W Holt; Bruce Kaplan; Dirk Kuypers; Bruno Meiser; Burkhard Toenshoff; Richard D Mamelok
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

Review 4.  Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

Authors:  M Oellerich; M Shipkova; E Schütz; E Wieland; L Weber; B Tönshoff; V W Armstrong
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

5.  Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.

Authors:  E J Schweitzer; S Yoon; J Fink; A Wiland; L Anderson; P C Kuo; J W Lim; L B Johnson; A C Farney; M R Weir; S T Bartlett
Journal:  Transplantation       Date:  1998-01-27       Impact factor: 4.939

6.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

7.  Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients.

Authors:  Eun Kyung Cho; Duck Jong Han; Song Cheol Kim; Gilbert J Burckart; Raman Venkataramanan; Jung Mi Oh
Journal:  J Clin Pharmacol       Date:  2004-07       Impact factor: 3.126

8.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.

Authors:  Chantal Le Guellec; Hélène Bourgoin; Matthias Büchler; Yann Le Meur; Yvon Lebranchu; Pierre Marquet; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.

Authors:  Guido Filler
Journal:  Transpl Int       Date:  2004-01-29       Impact factor: 3.782

View more
  5 in total

1.  Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms.

Authors:  Manop Pithukpakorn; Tiwat Tiwawanwong; Yupaporn Lalerd; Anunchai Assawamakin; Nalinee Premasathian; Adis Tasanarong; Wanna Thongnoppakhun; Attapong Vongwiwatana
Journal:  Pharmgenomics Pers Med       Date:  2014-12-05

2.  Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.

Authors:  Hongping Xiang; Hong Zhou; Jing Zhang; Yongfeng Sun; Yirong Wang; Yong Han; Jie Cai
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

3.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

4.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

5.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.